Susquehanna International Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$705K Buy
17,737
+6,174
+53% +$158K ﹤0.01% 8799
2025
Q4
$289K Buy
+11,563
New +$293K ﹤0.01% 10035
2025
Q2
Sell
-899,505
Closed -$11.4M 12768
2025
Q1
$12.9M Buy
899,505
+883,759
+5,613% +$14.5M ﹤0.01% 2216
2024
Q4
$264K Sell
15,746
-12,138
-44% -$201K ﹤0.01% 10108
2024
Q3
$446K Buy
+27,884
New +$342K ﹤0.01% 8744
2023
Q2
Sell
-12,616
Closed -$48.6K 12184
2023
Q1
$48.6K Buy
+12,616
New +$46.2K ﹤0.01% 11709

Other funds holding CNTA

Susquehanna International Group's CNTA Position: Q1 2026 in Review

Susquehanna International Group increased its Centessa Pharmaceuticals (CNTA) stake by 53% in Q1 2026, buying an estimated $158K and bringing the position to 17,737 shares worth $705K. The position accounts for ﹤0.01% of the portfolio, ranked #8799.

Susquehanna International Group first reported a position in CNTA in Q1 2023 and has held it in 6 quarters since. The position peaked at $12.9M in Q1 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Susquehanna International Group held 17,737 shares of Centessa Pharmaceuticals worth $705K as of Q1 2026.
  • Susquehanna International Group bought 6,174 Centessa Pharmaceuticals shares in Q1 2026, an estimated $158K.
  • Centessa Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8799 holding.
  • Susquehanna International Group first reported a position in Centessa Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Susquehanna International Group's Centessa Pharmaceuticals position peaked at $12.9M in Q1 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.